• 1
    US Cancer Statistics Working Group. United States Cancer Statistics: 1999-2010 Incidence and Mortality Web-based Report. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2013. Accessed February 25, 2014.
  • 2
    Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011;103:117-128.
  • 3
    Ekwueme DU, Guy GP, Li C, Rim SH, Parelkar P, Chen SC. The health burden and economic costs of cutaneous melanoma mortality by race/ethnicity–United States, 2000 to 2006. J Am Acad Dermatol. 2011;65(5 suppl 1):S133-S143.
  • 4
    US Preventive Services Task Force. Screening for Colorectal Cancer. Rockville, MD: Agency for Healthcare Research and Quality; 2008. Accessed March 2, 2013.
  • 5
    Lansdorp-Vogelaar I, Knudsen AB, Brenner H. Cost-effectiveness of colorectal cancer screening. Epidemiol Rev. 2011;33:88-100.
  • 6
    Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, Habbema JDF, Kuipers EJ. Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. J Natl Cancer Inst. 2009;101:1412-1422.
  • 7
    Dobson A, Sen N, DaVanzo J. Methodology for Estimating the Potential Cost Savings to Medicare from Increased Colorectal Cancer Screening of the Pre-Medicare Population. Accessed March 2, 2013.
  • 8
    Stanley SL, King JB, Thomas CC, Richardson LC. Factors associated with never being screened for colorectal cancer. J Community Health. 2013;38:31-39.
  • 9
    Centers for Disease Control and Prevention (CDC). Cancer screening—United States, 2010. MMWR Morb Mortal Wkly Rep. 2012;61:41-45.
  • 10
    US Department of Health and Human Services. Healthy People 2020. Accessed March 12, 2013.
  • 11
    Koh HK, Sebelius KG. Promoting prevention through the Affordable Care Act. N Engl J Med. 2010;363:1296-1299.
  • 12
    Sabatino SA, Lawrence B, Elder R, et al; Community Preventive Services Task Force. Effectiveness of interventions to increase screening for breast, cervical, and colorectal cancers: 9 updated systematic reviews for the guide to community preventive services. Am J Prev Med. 2012;43:97-118.
  • 13
    Levin TR, Jamieson L, Burley DA, Reyes J, Oehrli M, Caldwell C. Organized colorectal cancer screening in integrated health care systems. Epidemiol Rev. 2011;33:101-110.
  • 14
    Gupta S, Halm EA, Rockey DC, et al. Comparative effectiveness of fecal immunochemical test outreach, colonoscopy outreach, and usual care for boosting colorectal cancer screening among the underserved: a randomized clinical trial. JAMA Intern Med. 2013;173:1725-1732.
  • 15
    Benson VS, Patnick J, Davies AK, Nadel MR, Smith RA, Atkin WS. Colorectal cancer screening: a comparison of 35 initiatives in 17 countries. Int J Cancer. 2008;122:1357-1367.
  • 16
    US Census Bureau. Single Years of Age and Sex: 2010. factfinder2. Accessed March 12, 2013.
  • 17
    Wilschut JA, Steyerberg EW, van Leerdam ME, Lansdorp-Vogelaar I, Habbema JDF, van Ballegooijen M. How much colonoscopy screening should be recommended to individuals with various degrees of family history of colorectal cancer?Cancer. 2011;117:4166-4174.
  • 18
    Cole S, Smith A, Wilson C, Turnbull D, Esterman A, Young GP. An advance notification letter increases participation in colorectal cancer screening. J Med Screen. 2007;14:73-75.
  • 19
    Lee JK, Reis V, Liu S, et al. Improving fecal occult blood testing compliance using a mailed educational reminder. J Gen Intern Med. 2009;24:1192-1197.
  • 20
    Van Rossum L, Van Rijn AF, Laheij R, et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology. 2008;135:82-90.
  • 21
    Yabroff KR, Washington KS, Leader A, Neilson E, Mandelblatt J. Is the promise of cancer-screening programs being compromised? Quality of follow-up care after abnormal screening results. Med Care Res Rev. 2003;60:294-331.
  • 22
    Myers RE, Turner B, Weinberg D, et al. Impact of a physician-oriented intervention on follow-up in colorectal cancer screening. Prev Med. 2004;38:375-381.
  • 23
    Turner B, Myers RE, Hyslop T, et al. Physician and patient factors associated with ordering a colon evaluation after a positive fecal occult blood test. J Gen Intern Med. 2003;18:357-363.
  • 24
    Centers for Medicare and Medicaid Services. Physician Fee Schedule Search HCPCS Code 11400-11646. Accessed April 10, 2013.
  • 25
    Zauber AG. Cost-effectiveness of colonoscopy. Gastrointest Endosc Clin N Am. 2010;20:751-770.
  • 26
    Levin TR, Zhao W, Conell C, et al. Complications of colonoscopy in an integrated health care delivery system. Ann Intern Med. 2006;145:880-886.
  • 27
    Regula J, Rupinski M, Kraszewska E, et al. Colonoscopy in colorectal-cancer screening for detection of advanced neoplasia. N Engl J Med. 2006;355:1863-1872.
  • 28
    Lieberman DA, Weiss DG, Bond JH, et al. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. N Engl J Med. 2000;343:162-168.
  • 29
    Subramanian S, Tangka FK, Hoover S, DeGroff A, Royalty J, Seeff LC. Clinical and programmatic costs of implementing colorectal cancer screening: evaluation of five programs. Eval Program Plann. 2011;34:147-153.
  • 30
    Levi Z, Birkenfeld S, Vilkin A, et al. A higher detection rate for colorectal cancer and advanced adenomatous polyp for screening with immunochemical fecal occult blood test than guaiac fecal occult blood test, despite lower compliance rate. A prospective, controlled, feasibility study. Int J Cancer. 2011;128:2415-2424.
  • 31
    Lieberman DA, Rex DK, Winawer SJ, Giardiello FM, Johnson DA, Levin TR; United States Multi-Society Task Force on Colorectal Cancer. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2012;143:844-857.
  • 32
    Pignone MP, Flitcroft KL, Howard K, Trevena LJ, Salkeld GP, St John DJ. Costs and cost-effectiveness of full implementation of a biennial faecal occult blood test screening program for bowel cancer in Australia. Med J Aust. 2011;194:180-185.
  • 33
    Pox C, Schmiegel W, Classen M. Current status of screening colonoscopy in Europe and in the United States. Endoscopy. 2007;39:168-173.
  • 34
    Maciosek MV, Solberg LI, Coffield AB, Edwards NM, Goodman MJ. Colorectal cancer screening: health impact and cost effectiveness. Am J Prev Med. 2006;31:80-89.
  • 35
    Subramanian S, Tangka FK, Hoover S, et al. International Comparison of Economic Assessments of Colorectal Cancer Screening Programs: Preliminary Results. Presented at the 2012 CDC National Cancer Conference; August 21-23, 2012; Washington, DC.
  • 36
    Levin TR. Optimizing colorectal cancer screening by getting FIT right. Gastroenterology. 2011;141:1551-1555.
  • 37
    Grubbs SS, Polite BN, Carney J Jr, et al. Eliminating racial disparities in colorectal cancer in the real world: it took a village. J Clin Oncol. 2013;31:1928-1930.
  • 38
    Cole SR, Tucker GR, Osborne JM, et al. Shift to earlier stage at diagnosis as a consequence of the National Bowel Cancer Screening Program. Med J Aust. 2013;198:327-330.
  • 39
    Hoerger TJ, Ekwueme DU, Miller JW, et al. Estimated effects of the National Breast and Cervical Cancer Early Detection Program on breast cancer mortality. Am J Prev Med. 2011;40:397-404.
  • 40
    Ekwueme DU, Gardner JG, Subramanian S, Tangka FK, Bapat B, Richardson LC. Cost analysis of the National Breast and Cervical Cancer Early Detection Program: selected states, 2003 to 2004. Cancer. 2008;112:626-635.
  • 41
    Jean-Jacques M, Kaleba EO, Gatta JL, Gracia G, Ryan ER, Choucair BN. Program to improve colorectal cancer screening in a low-income, racially diverse population: a randomized control trial. Ann Fam Med. 2012;10:412-417.